Lexicon Q1 net loss narrows to $1M on $21.1M revenue; pipeline on track

LEXICON PHARMACEUTICALS, INC.

2026-Q1 EPS reported $0.00 revenue$21,102,000

Total revenues $21.1M (vs $1.3M), including $20M Novo Nordisk milestone; net loss $1.0M (vs $25.3M).
Cash and investments $199.7M at March 31, 2026; $96.5M stock sale; $100M Hercules loan facility (initial $55M funded).
SONATA-HCM enrollment completion mid-2026; topline results expected Q1 2027.
ZYNQUISTA NDA resubmission for T1D mid-2026; potential approval in 2026.
LX9851 Phase 1 started by Novo Nordisk; $10M milestone earned; up to $1B in total milestones.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LEXICON PHARMACEUTICALS, INC. reported quarter ended March 31, 2026 results: revenue $21.1 million.

Period: quarter ended March 31, 2026
Revenue: $21.1 million
Result: reported results

Exact text from the filing

Total revenues were $21.1 million for the first quarter of 2026

View on SEC.gov

Browse all earnings releases →

LEXICON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001062822-26-000098

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.